0000000000088946

AUTHOR

Matthias Endres

0000-0001-6520-3720

showing 10 related works from this author

Systematic monitoring for detection of atrial fibrillation in patients with acute ischaemic stroke (MonDAFIS): a randomised, open-label, multicentre …

2021

Summary Background Systematic electrocardiogram (ECG) monitoring improves detection of covert atrial fibrillation in stroke survivors but the effect on secondary prevention is unknown. We aimed to assess the effect of systematic ECG monitoring of patients in hospital on the rate of oral anticoagulant use after 12 months. Methods In this investigator-initiated, randomised, open-label, parallel-group multicentre study with masked endpoint adjudication, we recruited patients aged at least 18 years with acute ischaemic stroke or transient ischaemic attack without known atrial fibrillation in 38 certified stroke units in Germany. Patients were randomly assigned (1:1) to usual diagnostic procedur…

Malemedicine.medical_specialtyepidemiology [Atrial Fibrillation]methods [Electrocardiography]Populationdiagnosis [Ischemic Stroke]030204 cardiovascular system & hematologyBrain Ischemia03 medical and health sciencesElectrocardiography0302 clinical medicineRisk FactorsInternal medicineIschaemic strokeAtrial Fibrillationdiagnosis [Brain Ischemia]medicineepidemiology [Brain Ischemia]HumansIn patientMyocardial infarctionddc:610educationepidemiology [Ischemic Stroke]Ischemic StrokeMonitoring PhysiologicAgedAged 80 and overeducation.field_of_studybusiness.industryphysiopathology [Ischemic Stroke]Hazard ratiodiagnosis [Atrial Fibrillation]Atrial fibrillationOdds ratioMiddle Agedmethods [Monitoring Physiologic]medicine.diseasephysiopathology [Atrial Fibrillation]physiopathology [Brain Ischemia]3. Good healthFemaleNeurology (clinical)Open labelbusiness030217 neurology & neurosurgery
researchProduct

Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countr…

2015

Summary Background The Global Burden of Disease Study 2013 (GBD 2013) aims to bring together all available epidemiological data using a coherent measurement framework, standardised estimation methods, and transparent data sources to enable comparisons of health loss over time and across causes, age–sex groups, and countries. The GBD can be used to generate summary measures such as disability-adjusted life-years (DALYs) and healthy life expectancy (HALE) that make possible comparative assessments of broad epidemiological patterns across countries and time. These summary measures can also be used to quantify the component of variation in epidemiology that is related to sociodemographic develo…

GerontologyMaleCHANGING RELATIONNutrition and DiseaseMESH : Life ExpectancyMESH : AgedECONOMIC-DEVELOPMENTPoison controlMESH: Global HealthGlobal HealthSocioeconomic FactorCommunicable DiseaseMESH : Chronic DiseaseHealth TransitionVoeding en ZiekteQuality-Adjusted Life YearSELF-RATED HEALTHMESH : Socioeconomic FactorsMedicineMESH : FemaleMESH: Mortality Premature2. Zero hungerMESH: Agededucation.field_of_studyMESH: Middle AgedMortality rateMedicine (all)GBD2013 diseases[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologieGeneral MedicineMiddle Aged3. Good healthMESH : Wounds and InjuriesEpidemiological transitionMESH: Quality-Adjusted Life YearsMESH: Communicable DiseasesNONCOMMUNICABLE DISEASESFemaleQuality-Adjusted Life YearsMESH: Life ExpectancyMESH: Health TransitionHumanMESH: Socioeconomic FactorsACUTE MYOCARDIAL-INFARCTIONMESH : MaleMORTALITY TRENDSPopulationMESH : Health TransitionCommunicable DiseasesArticleLife ExpectancyEUROPEAN-UNIONSDG 3 - Good Health and Well-beingGeneral & Internal MedicineSYSTEMATIC ANALYSISDisability-adjusted life yearHumansLife ScienceMESH : Middle AgedMortalityeducationPrematureMESH : Mortality PrematureVLAGAgedMESH: Humansbusiness.industryMortality PrematureMESH: Chronic DiseaseMESH : Communicable DiseasesWounds and InjurieMESH : HumansMESH : Quality-Adjusted Life YearsNon-communicable diseaseAged; Chronic Disease; Communicable Diseases; Female; Global Health; Humans; Male; Middle Aged; Mortality Premature; Quality-Adjusted Life Years; Socioeconomic Factors; Wounds and Injuries; Health Transition; Life Expectancy; Medicine (all)medicine.diseaseMESH: MaleLOW SOCIOECONOMIC-STATUSYears of potential life lostSocioeconomic Factors[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieMESH: Wounds and InjuriesChronic DiseaseLife expectancyRISK-FACTORSMESH : Global HealthWounds and Injuries[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessMESH: FemaleDemographyLancet
researchProduct

The Post-COVID-19 Functional Status scale: a tool to measure functional status over time after COVID-19

2020

Since the outbreak of the Coronavirus disease 2019 (COVID-19) pandemic, most attention has focused on containing transmission of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and addressing the surge of critically ill patients in acute care settings. Indeed, as of April 29th 2020, over 3 million confirmed cases have been accounted for globally [1]. In the coming weeks and months, emphasis will gradually involve also post-acute care of COVID-19 survivors. It is anticipated that COVID-19 may have a major impact on physical, cognitive, mental and social health status, also in patients with mild disease presentation [2]. Previous outbreaks of coronaviruses have been associate…

Pulmonary and Respiratory Medicine2019-20 coronavirus outbreakActivities of daily livingCoronavirus disease 2019 (COVID-19)Scale (ratio)IMPACTPneumonia ViralMeasure (physics)610 Medicine & healthMachine learningcomputer.software_genreDiagnostic Self EvaluationBetacoronavirusDiagnostic Self Evaluation03 medical and health sciences0302 clinical medicineSurveys and QuestionnairesActivities of Daily LivingCorrespondenceHumansMedicinePatient Reported Outcome Measures030212 general & internal medicinePandemicsCOVIDSARS-CoV-2business.industry10031 Clinic for AngiologyCOVID-19Recovery of FunctionPhysical Functional Performance030228 respiratory system2740 Pulmonary and Respiratory MedicineQuality of LifeFunctional statusArtificial intelligenceCoronavirus InfectionsbusinesscomputerCoronavirus Infections
researchProduct

Vascular effects of diet supplementation with plant sterols.

2008

Objectives The purpose of this study was to evaluate vascular effects of diet supplementation with plant sterol esters (PSE). Background Plant sterol esters are used as food supplements to reduce cholesterol levels. Their effects on endothelial function, stroke, or atherogenesis are not known. Methods In mice, plasma sterol concentrations were correlated with endothelial function, cerebral lesion size, and atherosclerosis. Plasma and tissue sterol concentrations were measured by gas-liquid chromatography-mass spectrometry in 82 consecutive patients with aortic stenosis. Results Compared with those fed with normal chow (NC), wild-type mice fed with NC supplemented with 2% PSE showed increase…

Apolipoprotein EAortic valveMalemedicine.medical_specialtyDiet therapyArteriosclerosisCardiovascular SystemBrain Ischemiachemistry.chemical_compoundMiceEzetimibeRisk FactorsInternal medicinepolycyclic compoundsmedicineAnimalsHumansEndotheliumAgedCholesterolbusiness.industryPhytosterolsSterolMice Inbred C57BLEndocrinologymedicine.anatomical_structurechemistryCirculatory systemDietary Supplementslipids (amino acids peptides and proteins)FemalePlant PreparationsCardiology and Cardiovascular MedicinebusinessBlood vesselmedicine.drugJournal of the American College of Cardiology
researchProduct

Membrane-type 1 metalloproteinase is upregulated in microglia/brain macrophages in neurodegenerative and neuroinflammatory diseases

2013

We previously reported that glioma cells induce the expression of membrane-type 1 metalloproteinase (MT1-MMP or MMP-14) in tumor-associated microglia/macrophages and promote tumor growth, whereas MMP-14 expression in microglia under physiological conditions is very low. Here, we show that the increase in MMP-14 expression is also found in microglia/macrophages associated with neurodegenerative and neuroinflammatory pathologies in mouse models as well as in human biopsies or post-mortem tissue. We found that microglial/macrophage MMP-14 expression was upregulated in Alzheimer's disease tissue, in active lesions of multiple sclerosis, and in tissue from stage II stroke as well as in the corre…

Pathologymedicine.medical_specialtyMicrogliabusiness.industryMultiple sclerosisNeurodegenerationHuman brainmedicine.diseaseCellular and Molecular Neurosciencemedicine.anatomical_structureDownregulation and upregulationGliomamedicineMacrophagebusinessNeuroinflammationJournal of Neuroscience Research
researchProduct

Primary stroke prevention worldwide:translating evidence into action

2021

Abstract: Stroke is the second leading cause of death and the third leading cause of disability worldwide and its burden is increasing rapidly in low-income and middle-income countries, many of which are unable to face the challenges it imposes. In this Health Policy paper on primary stroke prevention, we provide an overview of the current situation regarding primary prevention services, estimate the cost of stroke and stroke prevention, and identify deficiencies in existing guidelines and gaps in primary prevention. We also offer a set of pragmatic solutions for implementation of primary stroke prevention, with an emphasis on the role of governments and population-wide strategies, includin…

Global Burden of Disease03 medical and health sciences0302 clinical medicineNursingBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Neurology.Medicine030212 general & internal medicineStrokeHealth policyCause of deathEntire populationHealth professionalsbusiness.industryHealth PolicyPublic Health Environmental and Occupational HealthBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Neurologija.medicine.disease3. Good healthStrokeAction (philosophy)Stroke preventionOcclusive Cerebrovascular DiseaseLife course approachHuman medicinebusiness030217 neurology & neurosurgery
researchProduct

Intracerebral Hemorrhage and Outcome After Thrombolysis in Stroke Patients Using Selective Serotonin-Reuptake Inhibitors.

2017

Background and Purpose— Selective serotonin-reuptake inhibitors (SSRIs) impair platelet function and have been linked to a higher risk of spontaneous intracerebral hemorrhage—an association that may be augmented by oral anticoagulants (OAC). We aimed to assess whether preadmission treatment with SSRIs in patients with acute ischemic stroke is associated with post-thrombolysis symptomatic intracerebral hemorrhage (sICH) and functional outcome. Methods— A multicenter retrospective analysis was conducted in prospective registries of patients treated by thrombolysis within 4.5 hours of stroke onset. The association between preadmission treatment with SSRIs and sICH (ECASS II definition [Europe…

Malemedicine.medical_specialtytherapeutic use [Anticoagulants]medicine.medical_treatmentSubgroup analysisepidemiology [Cerebral Hemorrhage]Risk AssessmentCohort Studies03 medical and health sciencesadverse effects [Serotonin Uptake Inhibitors]0302 clinical medicineModified Rankin ScaleInternal medicinemedicineHumansThrombolytic Therapy030212 general & internal medicineddc:610610 Medicine & healthStrokeCerebral HemorrhageAgedRetrospective StudiesAdvanced and Specialized NursingIntracerebral hemorrhageAged 80 and overtherapy [Cerebral Hemorrhage]business.industryAnticoagulantsThrombolysisOdds ratioMiddle Agedmedicine.diseaseadverse effects [Selective Serotonin Reuptake Inhibitors]Prognosisdrug therapy [Stroke]StrokeTreatment OutcomeAnesthesiaConcomitantSerotonin Uptake InhibitorsFemaleNeurology (clinical)Cardiology and Cardiovascular Medicinebusiness030217 neurology & neurosurgerySelective Serotonin Reuptake Inhibitorsepidemiology [Stroke]Cohort study
researchProduct

Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risk…

2015

Summary Background The Global Burden of Disease, Injuries, and Risk Factor study 2013 (GBD 2013) is the first of a series of annual updates of the GBD. Risk factor quantification, particularly of modifiable risk factors, can help to identify emerging threats to population health and opportunities for prevention. The GBD 2013 provides a timely opportunity to update the comparative risk assessment with new data for exposure, relative risks, and evidence on the appropriate counterfactual risk distribution. Methods Attributable deaths, years of life lost, years lived with disability, and disability-adjusted life-years (DALYs) have been estimated for 79 risks or clusters of risks using the GBD 2…

MaleFine particulate matterNutrition and DiseaseMESH : SanitationHealth BehaviorDiseasesMESH: Metabolic DiseasesMESH: Global Health030204 cardiovascular system & hematologyMESH: Risk AssessmentGlobal HealthMESH : Nutritional StatusMESH: Occupational Exposure0302 clinical medicineUnsafe SexMESH: Risk FactorsRisk FactorsVoeding en ZiekteMedicineAir-pollutionMESH : Female030212 general & internal medicineMESH : Risk AssessmentSanitationWasting2. Zero hungerFactors de risc en les malaltiesMedicine (all)[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologiePublic Health Global Health Social Medicine and EpidemiologyGeneral MedicineMESH : Occupational DiseasesMESH: Nutritional StatusAll-cause mortalityMESH : Risk FactorshumanitiesEnvironmental Exposure; Female; Global Health; Health Behavior; Humans; Male; Metabolic Diseases; Nutritional Status; Occupational Diseases; Occupational Exposure; Risk Assessment; Risk Factors; Sanitation; Medicine (all)Tobacco smoking3. Good healthOccupational DiseasesNutritional StatuMESH : Occupational ExposureMESH : Metabolic DiseasesCohortFemalemedicine.symptomRisk assessmentBlood-pressureHumanMESH: Occupational DiseasesRisk factors in diseasesCoronary-heart-diseaseMESH : MaleMESH: Health BehaviorMESH: Environmental ExposureNutritional StatusPopulation healthBody-mass indexRisk Assessment03 medical and health sciencesHousehold cookingMetabolic DiseasesCardiovascular-diseaseEnvironmental healthGeneral & Internal MedicineOccupational Exposureparasitic diseasesLife ScienceMESH: SanitationHumansRisk factorMESH : Health BehaviorVLAGGBD2013MESH: Humansbusiness.industryRisk FactorGlobal Burden of Disease Study; 79 behavioural environmental and occupational and metabolic risksLong-term exposureMESH : HumansCAUSE-SPECIFIC MORTALITYEnvironmental ExposureMESH: MaleMetabolic DiseaseOccupational DiseaseFolkhälsovetenskap global hälsa socialmedicin och epidemiologiMALE BRITISH DOCTORSYears of potential life lostRelative riskMalaltiesMESH : Global HealthOUTDOOR AIR-POLLUTION[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessMESH : Environmental ExposureMESH: FemaleLancet
researchProduct

Global, regional, and national burden of stroke and its risk factors, 1990–2019 : a systematic analysis for the Global Burden of Disease Study 2019

2021

Background Regularly updated data on stroke and its pathological types, including data on their incidence, prevalence, mortality, disability, risk factors, and epidemiological trends, are important for evidence-based stroke care planning and resource allocation. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) aims to provide a standardised and comprehensive measurement of these metrics at global, regional, and national levels. Methods We applied GBD 2019 analytical tools to calculate stroke incidence, prevalence, mortality, disability-adjusted life-years (DALYs), and the population attributable fraction (PAF) of DALYs (with corresponding 95% uncertainty intervals [UIs]…

MaleAging030204 cardiovascular system & hematologyStroke dataGUIDELINES3124 Neurology and psychiatryBody Mass IndexGlobal Burden of Disease0302 clinical medicineRA0421Risk FactorsEpidemiologyStrokesYOUNG-ADULTSPrevalence80 and overAetiology610 Medicine & healthStrokePOPULATION1103 Clinical Sciences 1109 NeurosciencesCause of deathAged 80 and overeducation.field_of_studyMortality rateIncidence (epidemiology)Incidence1. No povertyArticlesHälsovetenskaperMiddle AgedStroke typesddc:3. Good healthStrokeISCHEMIC-STROKEIncomeFemaleQuality-Adjusted Life YearsLife Sciences & BiomedicineAdultmedicine.medical_specialtyGBDPopulationClinical SciencesClinical Neurology610 Medicine & health03 medical and health sciencesClinical ResearchMIDDLE-INCOME COUNTRIESHealth SciencesmedicineHumansRisk factoreducationGBD 2019 Stroke CollaboratorsCerebral HemorrhageAgedIschemic StrokeGlobal burdenScience & TechnologyNeurology & NeurosurgeryHYPERTENSIONbusiness.industryMORTALITYPrevention3112 NeurosciencesNeurosciences1103 Clinical SciencesSERVICESSubarachnoid Hemorrhagemedicine.diseasePREVENTIONBrain DisordersGood Health and Well BeingAttributable riskHuman medicineNeurology (clinical)Neurosciences & Neurologybusiness1109 Neurosciences030217 neurology & neurosurgeryDemography2.4 Surveillance and distributionRC
researchProduct

Faim2 contributes to neuroprotection by erythropoietin in transient brain ischemia.

2018

Delayed cell death in the penumbra region of acute ischemic stroke occurs through apoptotic mechanisms, making it amenable to therapeutic interventions. Fas/CD95 mediates apoptotic cell death in response to external stimuli. In mature neurons, Fas/CD95 signaling is modulated by Fas-apoptotic inhibitory molecule 2 (Faim2), which reduces cell death in animal models of stroke, meningitis, and Parkinson disease. Erythropoietin (EPO) has been studied as a therapeutic strategy in ischemic stroke. Erythropoietin stimulates the phosphatidylinositol-3 kinase/Akt (PI3K/Akt) pathway, which regulates Faim2 expression. Therefore, up-regulation of Faim2 may contribute to neuroprotection by EPO. Male Faim…

Male0301 basic medicinemetabolism [Apoptosis Regulatory Proteins]FAIM2 protein humanlifeguard protein mouseIschemiaNerve Tissue Proteinspathology [Ischemic Attack Transient]physiology [Neuroprotection]PharmacologyBiochemistryNeuroprotectionmetabolism [Erythropoietin]metabolism [Ischemic Attack Transient]Brain ischemiaMice03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicinemedicineAnimalsHumansddc:610ErythropoietinStrokeProtein kinase BPI3K/AKT/mTOR pathwayAgedpharmacology [Erythropoietin]Mice Knockoutmetabolism [Nerve Tissue Proteins]business.industryPenumbraMembrane ProteinsMiddle Agedmedicine.diseaseNeuroprotection030104 developmental biologyIschemic Attack TransientErythropoietinphysiopathology [Ischemic Attack Transient]FemaleDose-dependency ; Erythropoietin ; Fas-apoptotic Inhibitory Molecule 2 ; Ischemia-reperfusion ; Neuroprotection ; StrokeApoptosis Regulatory Proteinsbusinessmetabolism [Membrane Proteins]030217 neurology & neurosurgerymedicine.drug
researchProduct